Tag Archives: Pharmaceutical law

Electronics vs. Biotech – Two Perspectives on “Patent Reform”

The most interesting session I attended today at the AUTM Annual Meeting was one on patent reform. What was most interesting was not a recap of the aspects of S.515, which is the most up-to-date reform bill pending, but the … Continue reading

Posted in Patent Reform Legislation | Tagged , , , , , , , , | Leave a comment

Federal Circuit Reverses District Court in Prometheus v. Mayo

On September 16, 2009, the Federal Circuit reversed the holding of the district court that a process for monitoring and adjusting a method of medical treatment was unpatentable as attempting to claim non-statutory subject matter (Prometheus Labs., Inc. v. Mayo … Continue reading

Posted in Patenting Methods/Processes | Tagged , , , , , , | Leave a comment

GENERICS (UK) LTD V DAIICHI PHARMACEUTICAL CO LTD – ENANTIOMER OF A KNOWN COMPOUND HELD PATENTABLE BY UK COURT OF APPEAL

By Paul Cole The present dispute concerned the patentability of the enantiomeric quinoline antibiotic levofloxacin covered by Daiichi’s expired EP (UK) 0206283 and by a supplementary protection certificate (SPC) based on it. The racemic compound ofloxacin was known, and the … Continue reading

Posted in Non-U.S. Practice | Tagged , , , , , , , , , | Leave a comment